Zobrazeno 1 - 10
of 26
pro vyhledávání: ''
Autor:
Zahra Mahmoudjafari, Al-Ola Abdallah, Cassie Remker, Monia Sigle, Ghulam Rehman Mohyuddin, Joseph P. McGuirk, Emily Coggins, Siddhartha Ganguly, Leyla Shune
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e220-e226
Background Aggressive relapsed/refractory multiple myeloma (RRMM) often requires salvage cytotoxic chemotherapy. We evaluated the efficacy and toxicity of VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) with a
Autor:
Hayri Bostan, Funda Pepedil Tanrikulu, Kevser Kut, Tulin Firatli-Tuglular, Fergun Yilmaz, F. Arikan, Isik Kaygusuz Atagunduz, Tayfur Toptas
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:836-842
With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and gender-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse ev
Autor:
Meletios A. Dimopoulos, Kari Remes, Joana Parreira, Pamela Bacon, Eleni Tholouli, Bjorn Andreasson, Gianpietro Semenzato, Gerard Crotty, Elisabeth Kueenburg, Christian Berthou, Miguel T. Hernandez, Monique C. Minnema, Sarah Peters, Antonia Di Micco, B. Rosettani, Igor Wolfgang Blau, Roman Hájek, Jo Caers, Barbara Gamberi
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2020, 20 (10), pp.e629-e644. ⟨10.1016/j.clml.2020.05.006⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2020, 20 (10), pp.e629-e644. ⟨10.1016/j.clml.2020.05.006⟩
Introduction Lenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile of lenalidomide plus de
Autor:
R J Ma, Jianmin Guo, Zhongwen Liu, Xiangli Chen, L Jiang, Jie Shi, X L Yuan, Jing Yang, Zunmin Zhu, Yin Zhang, Xiaojian Zhu, Yuzhu Zang, Pingchong Lei, Shiwei Yang, Lin Zhang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e382-e391
Introduction The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL). Patients and Met
Autor:
Aaron S. Rosenberg, Brian A. Jonas, Mehrdad Abedi, Julian R Davis, Rasmus T. Hoeg, Joseph Tuscano
Publikováno v:
Clin Lymphoma Myeloma Leuk
Clinical lymphoma, myeloma & leukemia, vol 20, iss 7
Clinical lymphoma, myeloma & leukemia, vol 20, iss 7
Introduction Everolimus and bendamustine both have single-agent activity against lymphoid hematologic malignancies. We examined this combination in a group of heavily pretreated patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and mul
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e526-e531
Background Similar to the application of other generic drugs, the use of generic imatinib in the treatment of chronic myeloid leukemia (CML) leads to significant cost savings, but it also raises issues related to efficacy, safety, and quality. This s
Autor:
Sagar Lonial, Sundar Jagannath, Jacalyn Rosenblatt, Asher Chanan-Khan, Nikhil C. Munshi, Todd M. Zimmerman, Sikander Ailawadhi, Faiza Rharbaoui, Andrea Wartenberg-Demand, Thomas Haeder, Kenneth C. Anderson, Markus Ruehle, Leonard T. Heffner
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:372-380
Background Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. Patients and Methods We report from 2 clinical studies of patients with relapsed and/or refractory MM
Autor:
Saad Z. Usmani, Sundar Jagannath, Clarissa M. Uhlar, G. Morgan, Imran Khan, Huaibao Feng, Donna Catamero, Suzanne Arinsburg, Parul Doshi, Ivey Treadwell, Toshihisa Satta, Ajai Chari
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:44-51
Introduction Daratumumab, a human CD38 monoclonal antibody approved for multiple myeloma (MM) treatment, binds red blood cells (RBCs), resulting in panagglutination in compatibility tests. Published mitigation methods avoid additional testing, ensuri
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:e55-e61
Introduction Generic imatinib therapy is being globally considered owing to cost considerations. However, evidence of its efficacy and safety in Middle Eastern clinical settings is scarce. Patients and Methods The efficacy and safety of generic imati
Autor:
Reda Bouabdallah, Razelle Kurzrock, Yu Jiang, David A. Rizzieri, Bruno Delafont, Martin J. S. Dyer, Seung Tae Lee, Amjad Hayat, Larry Bacon, Vincent Ribrag, Stephanie Anyanwu, Kowser Miah, Oday Hamid, Brian T. Hess, Leslie A. Andritsos, Pablo Martinez, Luis Fayad
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:309-317.e3
Background Despite recent advances, outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) remain poor. Immune checkpoint inhibitors have shown limited efficacy in this setting, but combinations with novel agents may enha